Zejula is an oral poly (ADP-ribose) polymerase (PARP) inhibitor. PARP inhibitors work by disabling the compromised DNA repair mechanisms of BRCA-mutated cancer cells, leading to cell death. Ovarian cancer tumors with normal BRCA genes but another homologous recombination deficiency (HRD) that disturbs normal DNA repair are also susceptible to PARP inhibitors. Zejula is indicated for maintenance therapy in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, regardless of tumor biomarker status.
If you have a Hayes login, click here to view the full report on the Knowledge Center.